KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) EBIT Margin (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of EBIT Margin data on record, last reported at 21.25% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 372.0% year-over-year to 21.25%; the TTM value through Dec 2025 reached 0.85%, down 1676.0%, while the annual FY2025 figure was 10.08%, 2769.0% down from the prior year.
  • EBIT Margin reached 21.25% in Q4 2025 per JAZZ's latest filing, up from 65.64% in the prior quarter.
  • Across five years, EBIT Margin topped out at 26.68% in Q1 2021 and bottomed at 65.64% in Q2 2025.
  • Average EBIT Margin over 5 years is 5.94%, with a median of 11.43% recorded in 2022.
  • Peak YoY movement for EBIT Margin: skyrocketed 6215bps in 2021, then tumbled -8512bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 5.51% in 2021, then crashed by -592bps to 27.09% in 2022, then surged by 145bps to 12.11% in 2023, then surged by 45bps to 17.53% in 2024, then increased by 21bps to 21.25% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 21.25% in Q4 2025, 65.64% in Q2 2025, and 17.53% in Q4 2024.